Ambisome (Amphotericin B Liposome) 50 mg Vial is an antifungal medication used to treat severe and potentially life-threatening fungal infections, such as aspergillosis, candidiasis, and cryptococcal meningitis. The liposomal formulation enhances the drug’s delivery, improving efficacy while minimizing the renal toxicity typically associated with conventional amphotericin B. Ambisome is often used in patients with weakened immune systems, including those undergoing chemotherapy or organ transplants. It is administered intravenously in a hospital setting to ensure close monitoring.
Ambisome® (Amphotericin B Liposome for Injection) by Astellas Pharma presents a revolutionary advancement in antifungal therapy. Designed to combat severe and potentially life-threatening fungal infections, Ambisome offers the powerful efficacy of amphotericin B in a liposomal formulation. This innovation enhances drug delivery while minimizing toxicity, making it a preferred choice among healthcare professionals. Packaged in convenient 50 mg single-dose vials, Ambisome requires refrigeration to maintain its stability and potency until use.
Product Details and Features:
Concentration and Packaging: Each vial contains 50 mg of amphotericin B encapsulated in a liposomal delivery system. Available in a single-dose 20 mL vial format.
Storage Requirements: Must be stored refrigerated to preserve the integrity of the liposomal encapsulation and maintain drug efficacy.
Brand: Developed and manufactured by Astellas Pharma, a leader in global healthcare solutions committed to innovative treatments.
Formulation Benefits: The liposomal delivery system significantly reduces the nephrotoxicity and infusion-related reactions commonly associated with conventional amphotericin B.
Mechanism of Action:
Ambisome works by binding to ergosterol, a crucial component of fungal cell membranes, disrupting membrane integrity and leading to cell death. The liposomal formulation allows targeted delivery of amphotericin B to fungal cells, while sparing human cells, thereby enhancing therapeutic benefits and reducing toxicity. Liposomes also enable prolonged circulation time in the bloodstream, increasing drug availability at infection sites.
Directions:
Dosage and Administration: Administer under the guidance of a qualified healthcare professional. Dosage varies based on the type and severity of the infection and patient response. Typically, Ambisome is administered intravenously.
Reconstitution: Follow specific guidelines for reconstituting and diluting the drug before infusion. Use aseptic techniques to ensure sterility.
Warnings:
-
Infusion-Related Reactions: Monitor patients closely during administration for any infusion-related reactions, which may include fever, chills, or rigors.
-
Renal Impairment: Ambisome has lower nephrotoxicity than traditional formulations, but caution is advised in patients with pre-existing renal impairment.
-
Anaphylaxis and Immune Precautions: There is a risk of anaphylactic reactions; ensure resuscitation equipment is available.
-
Pregnancy and Breastfeeding: Use only if the potential benefits justify the potential risk to the fetus or infant. Consult healthcare professionals when prescribing for pregnant or breastfeeding women.
Side Effects:
-
Common Effects: Fever, chills, hypokalemia (low potassium), and elevated serum creatinine levels may occur.
-
Serious Effects: Although rare, serious side effects can include nephrotoxicity, anaphylactic reactions, and severe infusion-related reactions.
-
Less Common: Abnormal liver function tests, headache, and nausea may be observed.
Ambisome by Astellas Pharma represents a significant advancement in the treatment of serious fungal infections, blending efficacy with improved safety through its liposomal encapsulation. Trust in Ambisome for reliable, compassionate care in antifungal therapy, backed by the pioneering reputation of Astellas Pharma.
Skip to content
